By Katherine Hamilton

Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication.

The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November.

The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial.

Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates.

Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 19, 2024 10:56 ET (15:56 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.